Dr. Rory M. Shallis
Claim this profileYale University
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
7 reported clinical trials
18 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
IDH positive
FLT3 positive
PML-RARA negative
2Acute Myeloid Leukemia
IDH positive
FLT3 positive
PML-RARA negative
Affiliated Hospitals
Clinical Trials Rory M. Shallis is currently running
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting1 award Phase 27 criteria
Screening Tool
for Myeloid Cancer
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Recruiting0 awards Phase 21 criteria
More about Rory M. Shallis
Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Rory M. Shallis has experience with
- Venetoclax
- Cytarabine
- Azacitidine
- Daunorubicin Hydrochloride
- Pembrolizumab
- Decitabine And Cedazuridine
Breakdown of trials Rory M. Shallis has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Myeloproliferative Disorder
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rory M. Shallis specialize in?
Rory M. Shallis focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved IDH positive patients, or patients who are FLT3 positive.
Is Rory M. Shallis currently recruiting for clinical trials?
Yes, Rory M. Shallis is currently recruiting for 2 clinical trials in New Haven Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Rory M. Shallis has studied deeply?
Yes, Rory M. Shallis has studied treatments such as Venetoclax, Cytarabine, Azacitidine.
What is the best way to schedule an appointment with Rory M. Shallis?
Apply for one of the trials that Rory M. Shallis is conducting.
What is the office address of Rory M. Shallis?
The office of Rory M. Shallis is located at: Yale University, New Haven, Connecticut 06520 United States. This is the address for their practice at the Yale University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.